Bronchiectasis and respiratory viral infections
Conditions
Interventions
None listed
Sponsors
Kyorin University Hospital
Japan Institute for Health Security
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with bronchiectasis who are 18 years of age or older, have had no exacerbations in the past 4 weeks, and have provided informed consent to participate in this study are eligible for inclusion. The diagnosis of bronchiectasis is based on chest HRCT findings of bronchiectasis and the presence of two of the following clinical symptoms: cough, sputum production, or a history of exacerbations.
Exclusion criteria
Exclusion criteria: Patients with cystic fibrosis, active tuberculosis, AIDS, those currently taking immunosuppressive drugs, those currently receiving systemic steroid therapy (equivalent to 20 mg/day or more of prednisolone on a daily basis), malignant tumors, or pulmonary fibrosis (traction bronchiectasis) are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint will be calculated as the odds ratio of respiratory virus detection rates by type during exacerbations and during stable periods. | — |
Secondary
| Measure | Time frame |
|---|---|
| In the secondary endpoints, we will compare the clinical characteristics of viral positive exacerbations and negative exacerbations (temporal changes in inflammatory markers, respiratory function, and quality of life scores [Quality of Life-Bronchiectasis; QOL-B], exacerbation frequency according to the severity of bronchiectasis [Bronchiectasis Severity Index; BSI], and frequency of severe exacerbations). Additionally, we will perform similar analyses for each viral strain. | — |
Countries
Japan
Contacts
Public ContactTatsuya Shirai
Japan Institute for Health Security Department of Respiratory Viruses
Outcome results
None listed